Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report released on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Aptose Biosciences in a research report on Wednesday, February 12th.

Aptose Biosciences Trading Down 10.7 %

NASDAQ:APTO opened at $3.25 on Tuesday. The stock has a 50 day simple moving average of $6.06 and a 200 day simple moving average of $8.95. The stock has a market cap of $208.98 million, a P/E ratio of -1.09 and a beta of 0.88. Aptose Biosciences has a 1-year low of $3.11 and a 1-year high of $58.18.

Institutional Trading of Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp boosted its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.